UNSPSC 51152010: Rapacuronium

This classification denotes a muscle relaxant with the molecular formula C37H61N2O4.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65Q4QDG4KC, chemically known as piperidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-3-(acetyloxy)-17-(1-oxopropoxy)-2-(1-piperidinyl)androstan-16-yl)-1-(2-propenyl)-, bromide but generally known as rapacuronium bromide, which bears US NIH Compound Identifier 177969.

UNSPSC 51152010 Rapacuronium, a Commodity code, does not align with the recent state and local solicitation activity tagged under it. The single recent opportunity on record—Seminole County, Florida's IFB60459723LAS—seeks Naloxone and safe drug deactivation systems, products that fall outside rapacuronium's pharmaceutical scope. The code shows little relevant recent activity for state and local procurement professionals evaluating opportunities in neuromuscular blocking agents or related pharmaceutical products.

Seminole County, Florida issued the sole recent solicitation under this code as an IFB with a response deadline of July 26, 2023, calling for annual procurement of 1,900 units of Naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford. The mismatch between the code's stated commodity (rapacuronium) and the actual procurement (Naloxone and drug deactivation systems) signals either a cataloging error in the source data or a significant divergence between code classification and purchasing practice. Vendors responding to similar opportunities should verify the actual scope of work directly from the issuing body's solicitation documents rather than relying on UNSPSC code designation alone.